Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2780-2787

  Blackhall, Fiona H ^a   Peters, Solange ^c   Bubendorf, Lukas ^d   Dafni, Urania ^f   Kerr, Keith M ^b   Hager, Henrik ^g   Soltermann, Alex ^e   O'Byrne, Kenneth J ^h   Dooms, Christoph ⁱ   Sejda, Aleksandra ^j   Hernández Losa, Javier ^k   Marchetti, Antonio ⁿ   Savic, Spasenija ^d   Tan, Qiang ^o   Thunnissen, Erik ^p   Speel, Ernst Jan M ^r   Cheney, Richard ^s   Nonaka, Daisuke ^a   De Jong, Jeroen ^q   Martorell, Miguel ^l   Letovanec, Igor ^c   Rosell, Rafael ^m   Stahel, Rolf A ^e   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF ATHENS   (Greece)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h ST JAMES S HOSPITAL   (Ireland)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l UNIVERSITY OF VALENCIA   (Spain)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁿ UNIVERSITY OF CHIETI   (Italy)

^o SHANGHAI JIAO TONG UNIVERSITY   (China)

^p VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^q NETHERLANDS CANCER INSTITUTE   (Netherlands)

^r MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; EUROPEAN; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TREATMENT OUTCOME; VERY ELDERLY; ADENOCARCINOMA; ENZYMOLOGY; EPIDEMIOLOGY; EUROPE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREVALENCE;

ADENOCARCINOMA; ADULT; AGED; COHORT STUDIES; EUROPE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84906812668     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.5921     Document Type: Article

References (33)

1. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 448:561-566, 2007
2. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
3. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med 368:2385-2394, 2013
4. Camidge DR, Kono SA, Flacco A, et al: Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581-5590, 2010
5. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with nonsmall- cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
6. Solomon B, Varella-Garcia M, Camidge DR: ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450-1454, 2009
7. Ou SH, Bartlett CH, Mino-Kenudson M, et al: Crizotinib for the treatment of ALK-rearranged nonsmall cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17:1351-1375, 2012
8. Peters S, Taron M, Bubendorf L, et al: Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 81:145-154, 2013
9. Scagliotti G, Stahel RA, Rosell R, et al: ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. Eur J Cancer 48:961-973, 2012
10. Thunnissen E, Bubendorf L, Dietel M, et al: EML4-ALK testing in non-small cell carcinomas of the lung: A review with recommendations. Virchows Arch 461:245-257, 2012
11. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307, 2010
12. Cabillic F, Gros A, Dugay F, et al: Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 9:295-306, 2014
13. Sequist LV, Heist RS, Shaw AT, et al: Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624, 2011
14. Varella-Garcia M, Berry LD, Su P-F, et al: ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. J Clin Oncol 30, 2012 (suppl; abstr 7589)
15. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
16. Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6:774-780, 2011
17. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13-17, 2008
18. Rodig SJ, Mino-Kenudson M, Dacic S, et al: Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223, 2009
19. Yang P, Kulig K, Boland JM, et al: Worse disease-free survival in never-smokers with ALK- lung adenocarcinoma. J Thorac Oncol 7:90-97, 2012
20. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823-859, 2013
21. Hirsch FR, Yatabe Y, Dietel M, et al: AKmonotheistic (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): An international consensus study. J Clin Oncol 31, 2013 (suppl; abstr e22042)
22. McLeer-Florin A, Moro-Sibilot D, Melis A, et al: Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol 7:348-354, 2012
23. Sholl LM, Weremowicz S, Gray SW, et al: Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8:322-328, 2013
24. Paik JH, Choe G, Kim H, et al: Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 6:466-472, 2011
25. To KF, Tong JH, Yeung KS, et al: Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J Thorac Oncol 8:883-891, 2013
26. Ying J, Guo L, Qiu T, et al: Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 24:2589-2593, 2013
27. Selinger CI, Rogers TM, Russell PA, et al: Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26:1545-1553, 2013
28. Tsao M, Hirsch F, Yatabe Y: IASLC Atlas of ALK Testing in Lung Cancer. Aurora, CO, IASLC Press, 2013
29. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
30. Lee JK, Park HS, Kim DW, et al: Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 118: 3579-3586, 2012
31. Kim HR, Shim HS, Chung JH, et al: Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118:729-739, 2012
32. Paik JH, Choi CM, Kim H, et al: Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76:403-409, 2012
33. Wu SG, Kuo YW, Chang YL, et al: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7:98-104, 2012